In this way, MMR actually contributes to CDDP cytotoxicity in tumour cells, and its downregulation results in acquired resistance, as defective MMR is associated with decreased CDDP cytotoxicity and poor prognosis in patients [226,227,228]. The gene discussed is MRC1; the disease is neoplasm.